Orlistat Disease Interactions

There are 4 disease interactions with orlistat:

Orlistat (Includes Orlistat) ↔ Malabsorption

Severe Potential Hazard, High plausibility

Applies to: Malabsorption Syndrome, Biliary Obstruction

The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.

References

  1. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.

Obesity Drugs (Includes Orlistat) ↔ Diabetics

Moderate Potential Hazard, High plausibility

Applies to: Diabetes Type 2

Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
  2. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
View all 9 references

Orlistat (Includes Orlistat) ↔ (Fat Soluble) Vitamin Deficiency

Moderate Potential Hazard, High plausibility

Applies to: Vitamin A Deficiency, Vitamin D Deficiency, Vitamin K Deficiency

At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.

References

  1. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.

Orlistat (Includes Orlistat) ↔ Nephrolithiasis

Moderate Potential Hazard, Moderate plausibility

Applies to: Nephrolithiasis

Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption. Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

References

  1. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.

You should also know about...

orlistat drug Interactions

There are 139 drug interactions with orlistat

orlistat alcohol/food Interactions

There is 1 alcohol/food interaction with orlistat

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2014 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)